When should prophylaxis therapy in inhibitor patients be considered?

Haemophilia

Volumn 17, Issue 5, 2011, Pages

  Young, G ^a   Auerswald, G ^b   Jimenez Yuste, V ^c   Konkle, B A ^d   Lambert, T ^e   Morfini, M ^f   Santagostino, E ^g   Blanchette, V ^h  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Hess Children's Hospital   (Germany)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d PUGET SOUND BLOOD CENTER   (United States)

^e BICÊTRE HOSPITAL   (France)

^f CAREGGI UNIVERSITY HOSPITAL   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

APCC; Inhibitors; Prophylaxis; Recommendations; RFVIIa; Treatment

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; NEUTRALIZING ANTIBODY; PROTHROMBIN;

ABSENCE OF SIDE EFFECTS; ARTHROPATHY; BLEEDING; DRUG HALF LIFE; HEMARTHROSIS; HEMOPHILIA; HUMAN; IMMUNOLOGICAL TOLERANCE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TREATMENT OUTCOME;

BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; FACTOR VIIA; HEMARTHROSIS; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; RECOMBINANT PROTEINS;

EID: 79961191771     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02494.x     Document Type: Review

References (45)

1. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
2. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med 2007; 357: 535-44.
3. Young G. New approaches in the management of inhibitor patients. Acta Haematol 2006; 115: 172-9.
4. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006; 12: 598-604.
5. Eichinger S, Lubsczyk B, Kollars M et al. Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa. Eur J Clin Invest 2009; 39: 707-13.
6. Hilgartner MW, Makipernaa A, Dimichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003; 9: 261-8.
7. Siegmund B, Richter H, Pollmann H. Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits? Haemophilia 2005; 11: 638-41.
8. Dimichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
9. Ohga S, Nomura A, Takada H, Suga N, Hara T. Successful self-infusion of activated prothrombin complex concentrate for prophylaxis in a child with a factor VIII inhibitor. Am J Hematol 2007; 82: 145-9.
10. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007; 13: 249-55.
11. Jiménez-Yuste V, Alvarez MT, Martín-Salces M et al. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia 2009; 15: 203-9.
12. Valentino LA. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia 2009; 15: 733-42.
13. Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 2001; 7: 517-22.
14. Brackmann HH, Effenberger E, Hess L, Schwaab R, Oldenburg J. Novoseven in immune tolerance therapy. Blood Coagul Fibrinolysis 2000; 11(Suppl. 1): S39-44.
15. Saxon BR, Shanks D, Jory CB, Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost 2001; 86: 1126-7.
16. Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia 2005; 11: 203-7.
17. Morfini M, Auerswald G, Kobelt RA et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 502-7.
18. Jimenez-Yuste V, Quintana M, Alvarez MT, Martin-Salces M, Hernandez-Navarro F. "Primary prophylaxis" with rFVIIa in a patient with severe haemophilia A and inhibitor. Blood Coagul Fibrinolysis 2008; 19: 719-20.
19. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in haemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
20. Almus FE, Rao LV, Fleck RA, Rapaport SI. Properties of factor VIIa/tissue factor complexes in an umbilical vein model. Blood 1990; 76: 354-60.
21. Almus FE, Rao LV, Rapaport SI. Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. Arterioscler Thromb 1993; 13: 105-11.
22. Gopalakrishnan R, Hedner U, Ghosh S et al. Bio-distribution of pharmacologically administered rFVIIa. J Thromb Haemost 2010; 8: 301-10.
23. Lopez-Vilchez I, Tusell J, Hedner U, Altisent C, Escolar G, Galan AM. Trafic of rFVIIa through endothelial cells and redistribution into subendotelium: implications for a prolonged hemostatic effect. J Coagulation Disorders 2009; 1: 1-6.
24. Mandal SK, Pendurthi UR, Rao LV. Cellular localization and trafficking of tissue factor. Blood 2006; 107: 4746-53.
25. Mandal SK, Pendurthi UR, Rao LV. Tissue factor trafficking in fibroblasts: involvement of protease-activated receptor-mediated cell signaling. Blood 2007; 110: 161-70.
26. Hoffman M, Colina CM, McDonald AG, Arepally GM, Pedersen L, Monroe DM. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost 2007; 5: 1403-8.
27. Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia 2004; 10(Suppl. 2): 3-9.
28. Valentino LA, Carcao M, Mathew P et al. The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report. Haemophilia 2009; 15: 959-65.
29. Perry D, Berntorp E, Tait C et al. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations. Haemophilia 2010; 16: 80-9 Sep 23. [Epub ahead of print]
30. Hoots WK, Ebbesen LS, Konkle BA et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14: 466-75.
31. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years''bonn protocol'. Vox Sang 1996; 70(Suppl. 1): 30-5.
32. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl. 1): 1-22.
33. DiMichele DM, Kroner BL, North American Immune Tolerance Study Group. The North American immune tolerance registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
34. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999; 77(Suppl. 1): 33-7.
35. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor eight bypassing activity. Thromb Haemost 1997; 77: 1113-19.
36. Lechner K, Nowotny C, Krinninger B, Zegner M, Deutsch E. Effect of treatment with activated prothrombin complex concentrate (FEIBA) on factor VIII-antibody level. Thromb Haemost 1979; 40: 478-85.
37. Gringeri A, Mannucci PM. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005; 11: 611-19.
38. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14: 671-84.
39. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
40. Di Michele DM, Goldberg I, Foulkes M, Hay CRM. International prospective randomized immune tolerance (ITI) study: preliminary results of therapeutic efficacy and safety. Haemophilia 2010; 16(Suppl. 4): 29.(abstract)
41. Ewenstein BM, Valentino LA, Journeycake JM et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004; 10: 629-48.
42. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10: 134-46.
43. Teitel J, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256-63.
44. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in haemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
45. Auerswald G, Morfini M. Prophylaxis with recombinant factor VII in haemophilia patients inhibitors. JCD 2010; 2: 1-8.